From Yahoo Finance: 2025-05-11 06:05:00

Eli Lilly and Visa are on track to reach a $1 trillion market cap by 2030 and have the potential to outperform long-term. Eli Lilly, a healthcare giant, faces challenges with tariffs and high valuation metrics. Despite this, the company is expected to maintain strong growth and deliver impressive returns beyond 2030.

Eli Lilly’s innovative weight management medicines and diversified pipeline position it for significant growth. The company’s focus on diabetes, anti-obesity, immunology, and oncology, along with promising gene therapy projects, make it an attractive investment. Eli Lilly’s strong dividend growth adds to its appeal for long-term investors.

Visa, a payment technology leader, aims to achieve a $1 trillion market cap by 2030 with an expected CAGR of 8.1%. The company’s fee-based revenue model benefits from inflation and e-commerce trends, making it well-suited to navigate market challenges. Visa’s strong network effect and growth prospects make it a top choice for long-term investors.

Investors should consider Eli Lilly and Visa for their long-term potential, despite potential challenges. While Eli Lilly faces headwinds, its growth prospects and innovative products make it an attractive investment. Visa’s dominance in payment technology, network effect, and growth opportunities position it as a solid choice for investors looking for steady returns.



Read more at Yahoo Finance: These 2 Stocks Will Join the Trillion-Dollar Club by 2030